Key result
Beta-adrenoceptor blocking agents can cause significant cardiorespiratory compromise in patients with pulmonary arterial hypertension due to poorly tolerated negative inotropic and chronotropic effects.
Why the study?
Does the use of beta-adrenoceptor blocking agents cause cardiorespiratory compromise in patients with pulmonary arterial hypertension and supraventricular tachycardia?
Population
Patients with pulmonary arterial hypertension and supraventricular tachycardia (SVT)
Design
Review
Authors
Loading...
May warrant avoiding beta-blockers for SVT in PAH; leaves open optimal rate-control strategies pending prospective trials.
Does the use of beta-adrenoceptor blocking agents cause cardiorespiratory compromise in patients with pulmonary arterial hypertension and supraventricular tachycardia?
Beta-blockers are potentially dangerous and can cause significant cardiorespiratory compromise when used to treat SVT in patients with pulmonary arterial hypertension.
Peacock et al. (2010) conducted a review in Pulmonary arterial hypertension. beta-Adrenoceptor blocking agents was evaluated on Cardiorespiratory compromise. Beta-adrenoceptor blocking agents can cause significant cardiorespiratory compromise in patients with pulmonary arterial hypertension due to poorly tolerated negative inotropic and chronotropic effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: